Search clinical trials for: Placebo for omalizumab

Total 69848 results

Hugh A Sampson, MD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

Milk Allergy

United States
Creighton University
Genentech, Inc.

Unknown

Effect of Xolair on Airway Hyperresponsiveness

Allergic Asthma

United States
Novartis Pharmaceuticals

Completed

Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy (X-ACT)

Angioedema | Chronic Spontaneous Urticaria

Germany
Stephen J. Teach, MD, MPH
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Omalizumab Before Onset of Exacerbations (OBOE)

Asthma in Children | Atopy | Viral Upper Respiratory Infection

United States
Massachusetts General Hospital
Genentech, Inc.

Completed

Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis

Nasal Polyps | Chronic Rhinosinusitis

United States
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Not yet recruiting

Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
University of Chicago
Genentech, Inc.; Novartis Pharmaceuticals

Completed

Xolair in Patients With Chronic Sinusitis

Sinusitis

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.

Active, not recruiting

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH)

Peanut Allergy | Multi-food Allergy

United States
Novartis Pharmaceuticals

Completed

A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma

Allergic Asthma

Canada, Sweden
University Hospital Inselspital, Berne
Novartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-AC

Completed

Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients

Chronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous Urticaria

Switzerland
Yuhan Corporation

Completed

A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases

Atopic Healthy Subjects | Adult Subjects With Mild Allergic Diseases

Korea, Republic of
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients (MAP-X)

Food Allergy

United States
Johns Hopkins University
Genentech, Inc.

Terminated

Effect of Anti-IgE in Non-Allergic Asthma

Asthma

United States
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Effect of Omalizumab on Responses to Cat Allergen Challenge

Allergic Rhinitis

United States
Novartis Pharmaceuticals

Completed

Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma (NATAIR)

Asthma

France
National Jewish Health
Novartis

Withdrawn

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels

Pulmonary Disease, Chronic Obstructive

United States
University of Utah
Novartis Pharmaceuticals

Completed

A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

Esophagitis

United States
Genentech, Inc.

Completed

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) (EXACT)

Asthma
University of Mississippi Medical Center
Novartis

Completed

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

Asthma

United States
Genentech, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp (SCALP)

Psoriasis
Yuhan Corporation

Recruiting

A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases

Atopic Healthy Subjects | Adult Subjects With Mild Allergic Diseases

Korea, Republic of
Creighton University
Novartis

Unknown

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

Allergy

United States
TaiMed Biologics Inc.
Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research Center

Completed

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108)

Prevention of Infection With HIV-1

United States
Yuhan Corporation

Recruiting

A Single Dose, Phase 1 Study of YH35324 in Patients With Various Allergic Diseases

Allergic Disease | Chronic Spontaneous Urticaria | Cold Urticaria | Chronic Inducible Urticaria

Korea, Republic of
Creighton University
Novartis Pharmaceuticals

Completed

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Lung Disease

United States
National Institute of Allergy and Infectious Diseases...
Inner-City Asthma Consortium

Completed

Inner-City Anti-IgE Therapy for Asthma (ICATA)

Asthma

United States
Philippe Bégin
The Hospital for Sick Children; Centre de recherche du Centre hospitalier universitaire... and other collaborators

Recruiting

Omalizumab to Accelerate a Symptom-driven Multi-food OIT (BOOM)

Immunotherapy | Physiological Effects of Drugs | Food IgE-mediated Allergy | Omalizumab

Canada
Novartis Pharmaceuticals
Genentech, Inc.

Completed

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists (eXplore)

Allergic Asthma

United States, Sweden, United Kingdom, France, Canada, Germany, Netherlands
Clinica Universidad de Navarra, Universidad de...
Hospital General Universitario Gregorio Marañon; Hospital Clinic of Barcelona; Complejo Hospitalario de Navarra and other collaborators

Completed

Efficacy Study of Omalizumab in Cholinergic Urticaria (CUN-OMAL-UCOL)

Cholinergic Urticaria

Spain
Genentech, Inc.

Completed

A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma (AQUA)

Allergic Asthma
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Completed

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

Hypersensitivity | Allergy | Rhinitis | Hay Fever

United States
New York Medical College
Icahn School of Medicine at Mount Sinai

Completed

E-B-FAHF-2, Multi OIT and Xolair for Food Allergy (FAHF-2)

Food Allergy
Simon Francis Thomsen
Aarhus University Hospital

Recruiting

Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria (EXOTIC)

Chronic Spontaneous Urticaria | Chronic Urticaria, Idiopathic

Denmark
McMaster University
Novartis

Completed

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

Eosinophilic Bronchitis | Steroid and/or Prednisone Dependent Asthma

Canada
Helsinki University Central Hospital
Ida Montini foundation, www.tb-foundation.org

Completed

Comparison of Biologicals in Treatment of Severe Asthma (BiSA)

Asthma

Finland
Medical University of Silesia
Centrum Medyczne Andrzej Bożek

Not yet recruiting

Biologics and Sublingual Immunotherapy (BSIPL)

Asthma, Allergic
Novartis Pharmaceuticals

Completed

Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment (SUNRISE)

CHRONIC SPONTANEOUS URTICARIA

France
Novartis

Completed

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Asthma

Canada
Novartis
Genentech, Inc.; Tanox

Completed

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

Asthma

United States, Argentina, Germany
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Acute Upper Respiratory Infections

Russian Federation
Bernstein Clinical Research Center

Withdrawn

A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Allergy Induced Asthma
The University Clinic of Pulmonary and Allergic...

Unknown

Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions

Allergy | Immunotherapy | Omalizumab | Bee Venom

Slovenia
Stanford University

Completed

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis (OXAD)

Atopic Dermatitis

United States
Boston Children's Hospital
Stanford University

Completed

Xolair Treatment for Milk Allergic Children

Milk Allergy

United States
IRCCS Policlinico S. Matteo

Completed

Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome (IComaliz)

Interstitial Cystitis | Painful Bladder Syndrome

Italy
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)

Allergic Asthma

Japan
Genentech, Inc.

Completed

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

Peanut Hypersensitivity
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Omalizumab in the Treatment of Peanut Allergy

Peanut Allergy | Food Allergy

United States
Genentech, Inc.

Completed

A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

Asthma
University of North Carolina, Chapel Hill
Genentech, Inc.; National Institutes of Health (NIH)

Terminated

Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab

Asthma | Allergy

United States

Search clinical trials for: Placebo for omalizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations